Verification of the T50 Calciprotein Crystallization test: bias estimation and interferences

Area of Science:

• Clinical Chemistry
• In Vitro Diagnostics
• Biomarker Assay Development

Background:

• The T50 Calciprotein Crystallization test (T50 test) is a novel blood-based assay measuring calciprotein particle transitions.
• Currently, the T50 test is exclusively performed at the manufacturing site (Calciscon AG).
• Validation in routine clinical laboratories is essential for broader adoption.

Purpose of the Study:

• To assess the agreement and precision of the T50 test in a routine clinical laboratory setting.
• To evaluate potential interferences from common substances in serum samples.
• To compare laboratory performance against manufacturer claims.

Main Methods:

• Serum samples were analyzed at two laboratory sites to determine agreement.
• The CLSI EP15-A3 protocol was employed for precision evaluation.
• Interference testing involved spiking pooled serum with hemoglobin, bilirubin, lipids, and low molecular weight heparin (LMWH).

Main Results:

• Excellent agreement was observed between the two laboratories for T50 values.
• High precision was demonstrated in the clinically relevant lower T50 range (CV 6.4%).
• No significant interferences were detected from hemoglobin, bilirubin, lipids, or LMWH at typical clinical concentrations.

Conclusions:

• The T50 test demonstrates successful implementation and reliable performance in a routine laboratory.
• The observed precision and lack of interference align with manufacturer specifications.
• This study supports the T50 test's potential for wider clinical use.